Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

thyroid cancer

- PMLiVE

Eli Lilly announces $2.1bn investment in new manufacturing sites

The new sites will create around 500 jobs within the company

- PMLiVE

Eli Lilly and Incyte’s Olumiant approved by FDA for hospitalised COVID-19 patients

Nearly one million people with COVID-19 have been treated with Olumiant in approximately 15 countries worldwide

- PMLiVE

Gilead signs $300m deal with Dragonfly to advance immunotherapies

The partnership will make use of Dragonfly’s oncology and inflammatory disease research capabilities

- PMLiVE

Cancer Research UK drives innovation with Cancer Research Horizons

Industry partners will gain access to an extensive network of 4,000 world-leading cancer researchers

- PMLiVE

Sanofi and IGM Biosciences agree on deal potentially worth over $6bn

The deal focuses on research into oncology, immunology and inflammation targets

- PMLiVE

AstraZeneca to present new oncology data at AACR

The American Association for Cancer Research Annual Meeting takes place in New Orleans from 8-13 April 2022

- PMLiVE

Results from trial show Eli Lilly’s COVID-19 drug improves survival rates

The RECOVERY trial is the biggest study of COVID-19 treatments in the world, involving more than 47,000 participants in the UK

White paper: Are we prepared for the influx of CAR-Ts?

Download this white paper, in which we look at how market access and hospital processes will need to transform to accommodate the the influx of CAR-T therapies

Research Partnership

- PMLiVE

Eli Lilly launches the Institute for Genetic Medicine and a $700m facility investment

The US state-of-the-art facility will further the development of RNA and DNA-based treatments

- PMLiVE

Eli Lilly partners with breast cancer advocacy organisations to raise awareness of risk factors

More than 290,000 women and men are expected to be diagnosed with breast cancer in the US in 2022

- PMLiVE

Eli Lilly’s Omicron drug treatment gets emergency use authorisation from FDA

The drug can be used to treat adults with mild-to-moderate COVID-19, and children aged 12 or older, in specific emergency cases in non-hospital settings

- PMLiVE

Improving outcomes in oncology: patient centricity and mental health

A key challenge in healthcare is how to proactively address unmet needs using patient-centric campaigns and resources, particularly in a time when ‘in-person’ care is limited. How can this be...

Mednet Group

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links